目的 探討復(fù)方樟柳堿聯(lián)合康柏西普玻璃體腔給藥治療濕性老年性黃斑變性（AMD）的效果。方法 研究時間為2014年4月-2017年10月，采用隨機(jī)抽樣與回顧性研究方法，選擇在渭南市中心醫(yī)院眼科就診的濕性AMD患者144例作為研究對象，根據(jù)治療方法的不同分為研究組與對照組各72例，對照組給予康柏西普玻璃體腔給藥治療，研究組在對照組治療的基礎(chǔ)上聯(lián)合復(fù)方樟柳堿治療，兩組均治療14 d，記錄兩組預(yù)后與視力變化情況。結(jié)果 治療后研究組與對照組的總有效率分別為97.2%和84.7%，研究組顯著高于對照組，差異有統(tǒng)計學(xué)意義（P<0.05）。兩組經(jīng)過治療后視力都顯著提高，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；其中研究組的視力提高比對照組更加顯著，差異有統(tǒng)計學(xué)意義（P<0.05）。治療后研究組熒光素滲漏消失40例，減少30例，無變化2例；對照組分別為25例、30例與17例，對比有顯著差異（P<0.05）。結(jié)論 復(fù)方樟柳堿聯(lián)合康柏西普玻璃體腔給藥治療濕性AMD能提高視力，減少熒光滲漏的發(fā)生，提高治療效果，值得在臨床上推廣應(yīng)用。

Objective To investigate the effects of conbercept vitreous cavity administration combined with compound anisodine in the treatment of wet age-related macular degeneration (AMD). Methods The study time was from April 2014 to October 2017, Used the random sampling and retrospective research methods, 144 cases of patients with wet AMD were selected in our hospital and were divided into study group and control group with 72 cases in each groups accorded to the different treatment methods. The control group was given conbercept vitreous cavity administration treatment, and the study group were given the conbercept vitreous cavity administration combined with compound anisodine treatment, the visual acuity and prognosis in the two groups were recorded. Results The total effective rate of the study group and the control group after treatment was 97.2% and 84.7% respectively, and the study group was significantly higher than the control group (P<0.05). The visual acuity of the two groups after treatment were improved significantly, and the improvement of visual acuity in the study group weremore significant than that of the control group, and compared the difference were statistically significantly (P<0.05). After treatment, there were 40 cases of fluorescein leakage disappeared in the study group, 30 cases were reduced, 2 cases did not change. The control group was 25 cases, 30 cases and 17 cases, respectively that compared were significantly difference (P<0.05). Conclusion The conbercept vitreous cavity administration combined with compound anisodine in the treatment of wet AMD can improve vision, reduce the occurrence of fluorescence leakage, improve the therapeutic effect, which it is worthy of clinical application.